Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $3.1 million.

  • Keros Therapeutics' Free Cash Flow rose 11009.2% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.1 million, marking a year-over-year increase of 16110.96%. This contributed to the annual value of -$162.8 million for FY2024, which is 2821.72% down from last year.
  • As of Q3 2025, Keros Therapeutics' Free Cash Flow stood at $3.1 million, which was up 11009.2% from -$30.3 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Free Cash Flow peaked at $160.6 million during Q1 2025, and registered a low of -$46.3 million during Q4 2024.
  • Moreover, its 5-year median value for Free Cash Flow was -$24.8 million (2022), whereas its average is -$15.3 million.
  • As far as peak fluctuations go, Keros Therapeutics' Free Cash Flow crashed by 214250.32% in 2023, and later skyrocketed by 45293.37% in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' Free Cash Flow stood at -$19.7 million in 2021, then fell by 10.49% to -$21.8 million in 2022, then fell by 19.3% to -$26.0 million in 2023, then crashed by 78.07% to -$46.3 million in 2024, then soared by 106.73% to $3.1 million in 2025.
  • Its Free Cash Flow stands at $3.1 million for Q3 2025, versus -$30.3 million for Q2 2025 and $160.6 million for Q1 2025.